Tag: Spectrum

Cardiome Completes Enrollment in the Post Approval Safety Study SPECTRUM Evaluating Brinavess®

VANCOUVER, April 17, 2018 /PRNewswire/ – Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today announced completion of enrollment for the Phase 4 SPECTRUM study evaluating Brinavess® (vernakalant hydrochloride, IV), the Company’s antiarrhythmic drug for the rapid […]